塔卡亚苏动脉炎中的互白素-6和RANTES:治疗决策指南?
1Clinical Research Center for Rare Diseases "Aldo e Cele Daccò," Mario Negri Institute of Pharmacological Research, Bergamo, Italy.
Circulation
|July 7, 1999
概括
塔卡亚苏动脉炎患者的血清IL-6和RANTES水平升高,与疾病活性相关. 监测这些炎症标志物可能有助于调整塔卡亚苏动脉炎的治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
- 类风湿病学 类风湿病学
背景情况:
- 塔卡亚苏动脉炎涉及激活的淋巴细胞和细胞介导免疫.
- 了解细胞因子在T细胞激活中的作用对于塔卡亚苏动脉炎的发病过程至关重要.
研究的目的:
- 在T细胞激活中识别炎症性和化学吸引性细胞因子在塔卡亚苏动脉炎中.
- 为了确定这些细胞因子是否可以作为疾病活动的标记物,并预测恶化.
主要方法:
- 用ELISA测量了18名塔卡亚苏动脉炎患者的IL-6 (IL-6),IL-1β和RANTES的血清水平.
- 活跃疾病和缓解阶段之间的细胞因子水平与健康对照者的比较.
主要成果:
- 与对照组相比,在活跃的Takayasu动脉炎患者中观察到血清IL-6和RANTES的升高.
- 在缓解后,IL-6水平正常化,而RANTES水平仍然很高.
- 在所有受试者中,IL-1β都低于检测极限.
- 在IL-6,RANTES和疾病活性之间发现了显著的正相关性.
结论:
- 血清IL-6和RANTES与塔卡亚苏动脉炎疾病活动密切相关.
- 这些细胞因子可能会导致Takayasu动脉炎中的血管性病变.
- 监测IL-6和RANTES可以帮助临床医生优化治疗策略.
相关概念视频
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...


